Thanks for the article Ron-
Although I realize there is limited space in these blurbs,
I continue to be both amused and encouraged by how so many of these general media biopharma reporters don't even mention 113 as part of Ariad's portfolio-
Yes, I know it's officially pre-clinical, but the prospects are so compelling that it would seem to at least deserve a mention.
This indicates to me that a wide swath of the biopharma world haven't even started to seriously consider it yet, which only portends a positive response when presentations at forums like the WCLC begin to register.
Without getting to smug, I'd have to say we're at least ahead of that curve...